RecruitingPhase 1NCT06859710

THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy

Interactions Between Delta-9-THC and CBD: A Controlled Human Drug-administration Study Probing a Harm Reduction Strategy


Sponsor

University of California, Los Angeles

Enrollment

30 participants

Start Date

Nov 5, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this research is to assess the impact of CBD on the effects of THC.


Eligibility

Min Age: 21 YearsMax Age: 55 Years

Inclusion Criteria7

  • Male or non-pregnant and non-lactating females aged 21-55 years
  • Report cannabis use 1-7 days per week over the month prior to screening
  • Not currently seeking treatment for their cannabis use
  • History of inhaled cannabis use
  • Have a Body Mass Index from 18.5 - 34 kg/m2
  • Able to perform all study procedures
  • Must be using a contraceptive (hormonal or barrier methods)

Exclusion Criteria10

  • Meeting DSM-V criteria for severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, mild or moderate CUD
  • Evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and PI) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent.
  • Report using other illicit drugs in the prior 4 weeks
  • Current pain
  • Pregnancy
  • Currently enrolled in another research protocol
  • Not using a contraceptive method (hormonal or barrier methods)
  • Insensitivity to the cold water stimulus of the Cold Pressor Test
  • Any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history.
  • Not able to speak and read English

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo

Vaporized Placebo

DRUGTHC

Vaporized THC (20 mg)

DRUGCBD 20 mg

Vaporized CBD (20 mg)

DRUGCBD 40 mg

Vaporized CBD (40 mg)

DRUGCBD 80 mg

Vaporized CBD (80 mg)


Locations(1)

UCLA Center for Cannabis and Cannabinoids

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06859710


Related Trials